Clinical results have revealed the effect of laser tinib, a third-generation EGFR targeted treatment, on atypical EGFR gene ...

EGFR mutations, including L858R and T790M, are common in NSCLC. TKIs like erlotinib and gefitinib target these mutations but ...

Janssen-Cilag International NV, a Johnson & Johnson company, has submitted an application to the European Medicines Agency ...

Rybrevant (amivantamab) has been cleared in combination with chemotherapy for patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or L858R mutations who have previously ...

This would be for adult patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations following ...